Microfluidic Manufacture of Lipid-Based Nanomedicines.

ABSTRACT: Nanoparticulate technologies have revolutionized drug delivery allowing for passive and active targeting, altered biodistribution, controlled drug release (temporospatial or triggered), enhanced stability, improved solubilization capacity, and a reduction in dose and adverse effects. However, their manufacture remains immature, and challenges exist on an industrial scale due to high batch-to-batch variability hindering their clinical translation. Lipid-based nanomedicines remain the most widely approved nanomedicines, and their current manufacturing methods remain discontinuous and face several problems such as high batch-to-batch variability affecting the critical quality attributes (CQAs) of the product, laborious multistep processes, need for an expert workforce, and not being easily am

SUBMITTER: Osouli-Bostanabad K 

PROVIDER: S-EPMC9506151 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature